EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes

Megan E Yates iD, Hunter Waltermire, Kanako Mori, Zheqi Li iD, Yiting Li, Hannah Guzolik, Xiaosong Wang iD, Tiantong Liu, Jennifer M Atkinson iD, Jagmohan Hooda iD, Adrian V Lee iD, Steffi Oesterreich iD

Endocrinology · 2024

DOI: 10.1210/endocr/bqae111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, 2024. Verfasst von Megan E Yates und 11 weiteren Autor:innen. Beteiligte Einrichtung: Women's Cancer Research Center, Magee-Women Research Institute, Pittsburgh, PA 15213, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, The Breasties.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is a leading cause of female mortality and despite advancements in personalized therapeutics, metastatic disease largely remains incurable due to drug resistance. The estrogen receptor (ER, ESR1) is expressed in two-thirds of all breast cancer, and under endocrine stress, somatic ESR1 mutations arise in approximately 30% of cases that result in endocrine resistance. We and others reported ESR1 fusions as a mechanism of ER-mediated endocrine resistance. ER fusions, which retain the activation function 1- and DNA-binding domains, harbor ESR1 exons 1 to 6 fused to an in-frame gene partner resulting in loss of the ER ligand-binding domain (LBD). We demonstrate that in a no-special type (invasive ductal carcinoma [IDC]-NST) and an invasive lobular carcinoma (ILC) cell line, ER fusions exhibit robust hyperactivation of canonical ER signaling pathways independent of estradiol or antiendocrine therapies. We employ cell line models stably overexpressing ER fusions with concurrent endogenous ER knockdown to minimize endogenous ER influence. Cell lines exhibited shared transcriptomic enrichment in pathways known to be drivers of metastatic disease, notably MYC signaling. Cells expressing the 3′ fusion partners SOX9 and YAP1 consistently demonstrated enhanced growth and cell survival. ILC cells expressing the DAB2 fusion led to enhanced growth, survival, and migration, phenotypes not appreciated in the IDC-NST DAB2 model. Herein, we report that cell line activity is subtype-, fusion-, and assay-specific, suggesting that LBD loss, the fusion partner, and the cellular landscape all influence fusion activities. Therefore, it will be critical to assess fusion frequency in the context of the clinicopathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEstrogen Receptor alphaHumansFemaleCell Line, TumorPhenotypeYAP-Signaling ProteinsSOX9 Transcription FactorCarcinoma, Ductal, BreastOncogene Proteins, FusionSignal TransductionCarcinoma, LobularTranscription FactorsGene Expression Regulation, NeoplasticAdaptor Proteins, Signal TransducingLigandsCell Proliferation

Stichwörter der Autor:innen

ILCbreast cancerendocrine resistanceestrogen receptorfusionmetastasis

Substanzen

Estrogen Receptor alphaESR1 protein, humanYAP-Signaling ProteinsSOX9 Transcription FactorSOX9 protein, humanYAP1 protein, humanOncogene Proteins, FusionTranscription FactorsAdaptor Proteins, Signal TransducingLigands

Autor:innen und Institutionen

  • Women's Cancer Research Center, Magee-Women Research Institute, Pittsburgh, PA 15213, USA.
  • UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
  • Medical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
  • Integrative Systems Biology Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
  • Biomedical Masters Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
  • Physician Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

ORCID-Profile: Megan E Yates, Zheqi Li, Xiaosong Wang, Jennifer M Atkinson, Jagmohan Hooda, Adrian V Lee, Steffi Oesterreich

Förderung

  • NCI NIH HHS
  • NIH HHS
  • The Breasties
  • UPMC Hillman Cancer Biology Program
  • Hillman Foundation
  • Breast Cancer Alliance
  • Shear Family Foundation
  • Pennsylvania Department of Health

Zitieren

APA

Yates, M. E., Waltermire, H., Mori, K., Li, Z., Li, Y., Guzolik, H., Wang, X., Liu, T., Atkinson, J. M., Hooda, J., Lee, A. V., & Oesterreich, S. (2024). ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes. Endocrinology. https://doi.org/10.1210/endocr/bqae111

Vancouver

Yates ME, Waltermire H, Mori K, Li Z, Li Y, Guzolik H, et al. ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes. Endocrinology. 2024. doi:10.1210/endocr/bqae111

BibTeX
@article{Yates2024,
  author = {Yates, Megan E and Waltermire, Hunter and Mori, Kanako and Li, Zheqi and Li, Yiting and Guzolik, Hannah and Wang, Xiaosong and Liu, Tiantong and Atkinson, Jennifer M and Hooda, Jagmohan and Lee, Adrian V and Oesterreich, Steffi},
  title = {ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes},
  journal = {Endocrinology},
  year = {2024},
  doi = {10.1210/endocr/bqae111}
}
Kostenlos starten →